The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis

Mucositis Clinical Trial

Official title:

The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis in Patients With Gastrointestinal Tumors: a Prospective, Randomized, Controlled, Double-blind, Phase III Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04988971
• Other study ID #: 2021615
• Status: Recruiting
• Phase: Phase 3
• Start date: June 30, 2021
• Est. completion date: December 31, 2022

Study information

• Verified date: October 2021
• Source: West China Hospital
• Contact: meng qiu, Doctor
• Phone: 18980601776
• Email: qiumeng[@]wchscu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chemotherapy regimens not only improve the survival of patients with gastric cancer and colorectal cancer, but also cause obvious adverse reactions of digestive tract, such as chemotherapy-induced oral mucositis, abdominal pain, diarrhea, constipation and so on. These adverse reactions seriously affect the patients' quality of life and the efficacy of chemotherapy. Glutamine is a conditionally essential amino acid in the human body. Previous studies have shown that oral glutamine can help to keep the integrity of mucosal epithelium during chemotherapy and reduce the gastrointestinal side effects caused by chemotherapy. The addition of glutamine to parenteral nutrition can better maintain nitrogen balance and reduce the incidence of infection-related complications. A compound glutamine capsule, composed of L-glutamine and the traditional Chinese herbal formula Si-Jun-Zi-Tang which composed of ginseng, Atractylodes macrocephala, Poria cocos and licorice, has been widely used in China for 23 years to treat many types of gastrointestinal diseases, including gastrointestinal reactions induced by radiotherapy and chemotherapy, ulcerative colitis, irritable bowel syndrome. However, so far, only a small sample of clinical trials have explored the role of glutamine in chemical mucositis, and there is a lack of prospective randomized controlled clinical trials to further verify its value in the prevention and treatment of chemical mucositis. The purpose of this study is to observe the efficacy and safety between a compound glutamine capsule and placebo in the prevention of chemotherapy-induced mucositis in patients with gastric cancer and colorectal cancer in a prospective, randomized, double-blind clinical trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 31, 2022
• Est. primary completion date: July 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age: 18-75 years old; Sex: Male or female;
• Pathologically confirmed gastric adenocarcinoma or colorectal adenocarcinoma;
• Patients who had received standard chemotherapy containing platinum or irinotecan developed grade 1-3 (NCI-CTCAE, version4.0) diarrhea in the previous cycle and recovered to grade 0 after symptomatic treatment;
• Patients are planned to receive the same chemotherapy regimen and dose as the previous cycle;
• A baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
• Adequate haematopoietic function of bone marrow: neutrophils=1.5x109 / L, platelets=75x109 / L; normal liver and kidney function: TBIL= 1 upper limit of normal (ULN); ALT and AST =2.5 ULN; creatinine=1.5 ULN;
• Estimated life expectancy = 3 months;
• Be willing and able to provide written informed consent for the trial.

Exclusion Criteria:

• (Patient-Generated Subjective Global Assessment, PG-SGA)>9 or severe malnutrition (weight loss > 10% or serum albumin < 30 g/L or body mass index < 18.5 kg/m2);
• Patients with severe heart, lung and brain diseases; chronic hepatitis infection, liver cirrhosis, chronic nephritis, kidney dysfunction, etc;
• Patients with infection-related fever;
• Patients who are known to be allergic or intolerant to any of the ingredients used in the study;
• Patients with long-term chronic diarrhea, abdominal pain, constipation or other digestive tract diseases; patients with gastrointestinal symptoms before chemotherapy (=grade 2 NCI-CTCAE, version 4.0);
• Synchronously receive other treatments that may cause diarrhea, such as radiotherapy;
• Patients who take drugs for microecological regulation of digestive tract such as Combined Bifidobacterium, ChangTai oral liquid, etc;
• Patients take traditional Chinese medicine or antibiotics;
• Unable to understand and sign the informed consent form;
• participants in other clinical trials.

Related Conditions & MeSH terms

• Chemotherapeutic Toxicity
• Mucositis

Intervention

Drug:
• a compound glutamine capsule
A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
• a compound glutamine capsule simulated placebo
a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.

Locations

Country	Name	City	State
China	Meng Qiu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Meng Qiu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes of scores of Quality of Life Questionare-Core 30 of the European Organization for Research and Treatment of Cancer of patients between interventional group and control group before and after this cycle of chemotherapy	Changes of scores of Quality of Life Questionare-Core 30 of the European Organization for Research and Treatment of Cancer of patients between interventional group and control group before and after this cycle of chemotherapy	an average of 3 weeks
Other	Changes of fecal flora and enteritis-associated inflammatory factors	find the differences in the composition structure of the microbial community in the feces sample by 16SrDNA amplification techniques.Detect changes of calprotectin in patients in feces.	an average of 3 weeks
Primary	Overall incidence of chemotherapy-induced diarrhea = grade 1	Overall incidence of chemotherapy-induced diarrhea = grade 1 (according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0)	At the end of Cycle 1(each cycle is 14/21 days)
Secondary	Overall incidence of gastrointestinal adverse events except diarrhea = grade 1	Overall incidence of gastrointestinal adverse events except diarrhea = grade 1 (including oral mucositis, nausea, vomiting, abdominal pain, stomachache, and other types, according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0)	At the end of Cycle 1(each cycle is 14/21 days)
Secondary	Overall incidence of grade 3/4 gastrointestinal adverse events	Overall incidence of grade 3/4 gastrointestinal adverse events according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0	At the end of Cycle 1(each cycle is 14/21 days)